Latisse® eyelash growth
Introducing Latisse® the worlds first FDA approved minimally invasive treatment for eyelash growth.
To schedule your consultation with Dr. Parsa or for more information about Latisse®, simply contact our office today.
- What is LATISSE™ (bimatoprost ophthalmic solution) 0.03%?
- What is hypotrichosis of the eyelashes?
- How does LATISSE™ work?
- How do I apply LATISSE™?
- How soon will I see results?
- Is LATISSE™ a replacement for mascara?
- Is LATISSE™ different from nonprescription products that indicate eyelash growth?
- What if I forget to apply one night? Or a few nights?
- What happens if I stop using LATISSE™?
- Do I need to get a prescription for LATISSE™?
- What are the possible side effects of LATISSE™?
- What should I do if I get LATISSE™ in my eye?
- Who should NOT use LATISSE™?
- What are the ingredients in LATISSE™?
- What is skin hyperpigmentation?
- What is elevated intraocular pressure (IOP)?
LATISSE™ solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker.
Hypotrichosis is another name for having inadequate or not enough eyelashes.
The active ingredient in LATISSE™ is bimatoprost. Although the precise mechanism of action is not known, research suggests that the growth of eyelashes occurs by increasing the percent of hairs in, and the duration of, the anagen (or growth) phase. Lashes can grow longer, thicker and darker because bimatoprost can also prolong this growth phase.
LATISSE™ is a once-a-day treatment you apply yourself each evening to the base of the upper eyelashes. See the full instructions in How to Apply.
LATISSE™ users may see results starting at 4 weeks with full results after 16 weeks. The growth is gradual overnight, over time.
No, LATISSE™ does not work in place of mascara. However, mascara is a nice complement to LATISSE™ to help make your new longer eyelashes look even more attractive.
LATISSE™ solution is the first and only prescription treatment approved by the FDA for inadequate or insufficient eyelashes, growing them longer, fuller and darker.
If you miss an application or a few, don’t try to catch up. Just apply the LATISSE™ treatment the next evening and stay on schedule.
If you stop using LATISSE™, your eyelashes are expected to return to their previous appearance over several weeks to months.
Yes. You need to be examined by Dr. Parsa before he prescribes you LATISSE™. Dr. Parsa is an oculoplastic & Cosmetic Eyelid & Oculoplastic Surgeon. He can examine you and assess if you are a candidate for Lattise.
The most common side effects after using LATISSE™ solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately 4% of patients. LATISSE™ solution may cause other less common side effects which typically occur on the skin close to where LATISSE™ is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.
LATISSE™ solution is an ophthalmic drug product. If any gets into the eye, it is not expected to cause harm. The eye should not be rinsed.
Do not use LATISSE™ solution if you are allergic to one of its ingredients.
Active ingredient: bimatoprost. Inactive ingredients: benzalkonium chloride; sodium chloride; sodium phosphate, dibasic; citric acid; and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 — 7.8.
This is a common, usually harmless condition in which patches of skin become abnormally darker than the surrounding skin color. This occurs when an excess of melanin, the brown pigment that produces normal skin color, forms deposits in the skin. Hyperpigmentation is a possible side effect of LATISSE™, but may be reversible after you discontinue use.
This is a condition where the pressure inside the eye is higher than normal. LATISSE™ may decrease IOP. So make sure you let Dr. Parsa know if you have any ocular condition. Concurrent administration of LATISSE™ and certain IOP-lowering medications in ocular hypertensive patients should be closely monitored for changes in intraocular pressure.